Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS; Results of a Randomized Phase III Study

Borje S Andersson, MD, PhD, Marcos J de Lima, MD, Rima M Saliba, PhD, Elizabeth J Shpall, MD, Uday Popat, M.D., Roy Jones, MD, PhD, Yago Nieto, MD, PhD, Chitra M Hosing, MD, Partow Kebriaei, MD, Amin M Alousi, MD, Laura L. Worth, MD, PhD, Timothy Madden, Pharm.D., Alison Gulbis, Pharm.D., Julianne J Chen, Gabriela Rondon, MD, Patricia McAdams, RN, Becky McMullin, RN, Michael Andreeff, M.D., Ph.D., Richard Champlin, MD

Blood (2011) 118 (21): 892.

https://doi.org/10.1182/blood.V118.21.892.892

Published: 2011

Journal Articles

Inotuzumab Ozogamicin (IO) Is An Effective Salvage Therapy That Allows for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Remission in Patients with Advanced Acute Lymphoblastic Leukemia (ALL)

Partow Kebriaei, MD, Kaci Wilhelm, Farhad Ravandi, MD, Rima M. Saliba, PhD, Marcos De Lima, MD, Stefan O Ciurea, MD, Laura L. Worth, MD, PhD, Susan O'Brien, MD, Deborah A. Thomas, MD, Richard Champlin, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 3102.

https://doi.org/10.1182/blood.V118.21.3102.3102

Published: 2011

Journal Articles

High Rate of Engraftment and Low Regimen-Related Toxicity Using Fludarabine, Melphalan and Thiotepa Conditioning for Unrelated Donor Cord Blood Transplantation

Stefan O Ciurea, MD, Partow Kebriaei, MD, Issa F Khouri, MD, Muzaffar H. Qazilbash, MD, Roy B Jones, MD, Demetrios Petropoulos, MD, Laura L. Worth, MD, PhD, Amin M Alousi, MD, Chitra M Hosing, MD, Poliana Patah, MD, Pedro Cano, PhD, John McMannis, PhD, Sergio A Giralt, MD, Marcelo Fernandez-Vina, PhD, Richard E Champlin, MD, Elizabeth J. Shpall, MD, Marcos De Lima, MD

Blood (2008) 112 (11): 4414.

https://doi.org/10.1182/blood.V112.11.4414.4414

Published: 2008

Journal Articles

Clofarabine (Clo) +/− Fludarabine (Flu) with IV Busulfan (Bu) and Allogeneic Stem Cell Transplantation (Allo-SCT) for Relapsed, Refractory Myeloid Leukemia (ML) and MDS

Borje S. Andersson, MD, PhD, Marcos de Lima, MD, Laura L. Worth, MD, PhD, Uday Popat, MD, Roy B. Jones, MD, PhD, Elizabeth J. Shpall, MD, Chitra Hosing, MD, Timothy Madden, BS, PHARMD, Reza Kazerooni, RPH, Patricia McAdams, BSN, Amin Alousi, MD, Partow Kebriaei, MD, Richard E. Champlin, MD

Blood (2008) 112 (11): 4390.

https://doi.org/10.1182/blood.V112.11.4390.4390

Published: 2008

Journal Articles

Tacrolimus and Short-Term Methotrexate (mini-MTX) for Graft Versus Host Disease (GVHD) Prophylaxis after Unrelated Single Unit Cord Blood Transplant (CBT) in Pediatric Patients.

Demetrios Petropoulos, MD, Laura L. Worth, MD, PhD, Susannah E. Koontz, PharmD, Mary S. Choroszy, APN, Ka Wah Chan, MD, Elizabeth J. Shpall, MD, Richard E. Champlin, MD, Laurence J. Cooper, MD, PhD

Blood (2007) 110 (11): 5018.

https://doi.org/10.1182/blood.V110.11.5018.5018

Published: 2007

Journal Articles

Total Body Irradiation (TBI), Fludarabine (F), Melphalan (M) and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Advanced Pediatric Hematologic Malignancies.

Demetrios Petropoulos, MD, Laura L. Worth, MD, PhD, Craig A. Mullen, MD, PhD, Anita Mahajan, MD, Mary S. Choroszy, APN, Ka Wah Chan, MD

Blood (2004) 104 (11): 1827.

https://doi.org/10.1182/blood.V104.11.1827.1827

Published: 2004

NARROW

Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS; Results of a Randomized Phase III Study

Inotuzumab Ozogamicin (IO) Is An Effective Salvage Therapy That Allows for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Remission in Patients with Advanced Acute Lymphoblastic Leukemia (ALL)

High Rate of Engraftment and Low Regimen-Related Toxicity Using Fludarabine, Melphalan and Thiotepa Conditioning for Unrelated Donor Cord Blood Transplantation

Clofarabine (Clo) +/− Fludarabine (Flu) with IV Busulfan (Bu) and Allogeneic Stem Cell Transplantation (Allo-SCT) for Relapsed, Refractory Myeloid Leukemia (ML) and MDS

Tacrolimus and Short-Term Methotrexate (mini-MTX) for Graft Versus Host Disease (GVHD) Prophylaxis after Unrelated Single Unit Cord Blood Transplant (CBT) in Pediatric Patients.

Total Body Irradiation (TBI), Fludarabine (F), Melphalan (M) and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Advanced Pediatric Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS; Results of a Randomized Phase III Study

Inotuzumab Ozogamicin (IO) Is An Effective Salvage Therapy That Allows for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Remission in Patients with Advanced Acute Lymphoblastic Leukemia (ALL)

High Rate of Engraftment and Low Regimen-Related Toxicity Using Fludarabine, Melphalan and Thiotepa Conditioning for Unrelated Donor Cord Blood Transplantation

Clofarabine (Clo) +/− Fludarabine (Flu) with IV Busulfan (Bu) and Allogeneic Stem Cell Transplantation (Allo-SCT) for Relapsed, Refractory Myeloid Leukemia (ML) and MDS

Tacrolimus and Short-Term Methotrexate (mini-MTX) for Graft Versus Host Disease (GVHD) Prophylaxis after Unrelated Single Unit Cord Blood Transplant (CBT) in Pediatric Patients.

Total Body Irradiation (TBI), Fludarabine (F), Melphalan (M) and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Advanced Pediatric Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only